Japan: Aveo applies there for cancer drug; Vectura gets its approval for inhaler treatment;

@FiercePharma: Japan OKs Novo Nordisk's long-acting insulin Tresiba, still awaiting decision from FDA. More | Follow @FiercePharma

> Aveo Oncology and Japanese drug developer Astellas Pharma say Aveo has submitted a new drug application to the FDA for approval of tivozanib to treat kidney cancer. Story

> Vectura announced that Japan has approved its Seebri inhalation capsules used in inhaler devices and says they will be on the market there by the end of the year. Item

> South Africa's Medicines Control Council (MCC) has denied compassionate access to a TB drug that for many drug-resistant patients is their last hope. Story

> New Jersey has secured $2.6 million in federal grants to help laid off pharma workers get retrained and find new jobs, an announcement that follows Roche's ($RHHBY) decision to close an R&D center there. Story

Biotech News

@FierceBiotech: The French government wants Sanofi 'guarantees' on the future of Toulouse R&D. More | Follow @FierceBiotech

@JohnCFierce: Paratek - Ph3 antibiotic, lost a big Novartis deal last year - wants a $92M IPO? Hmmmm. More | Follow @JohnCFierce

@RyanMFierce: A crisis of credentials? Abbott came clean that choice to lead pharma unit didn't finish college. More | Follow @RyanMFierce

> IPO priced for biotech working on drug against chin fat. Story

> Novo Nordisk scuttles late-stage hemophilia drug over patient risk. Article

Medical Device News

@FierceMedDev: Boston Scientific won a CE mark for a Deep brain stimulation treatment of Parkinson's disease. More | Follow @FierceMedDev

@MarkHFierce: Finally--the deal is done. Sony is officially investing $645M into Olympus and the two will partner on medical equipment. More | Follow @MarkHFierce

@DamianFierce: The FDA is getting an earful from lawmakers over the hackability of medical devices. More | Follow @DamianFierce

> Medtronic makes a splash in China with $816M Kanghui buyout. Story

> A giant step forward for dissolvable medical devices. News

> Olympus, Sony ally on endoscope, med device development. Article

And Finally... Kythera Biopharmaceuticals is seeking $14 to $16 per share in its IPO to raise money to continue its development of an injected drug for elective treatments to wipe out chin fat. Story

Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.